Exploring Gene Therapy as a Potential Alzheimer's Prevention Method
Written on
Chapter 1: Understanding Alzheimer's and Genetic Risk
Alzheimer's disease remains a mystery, with no definitive causes identified. However, one well-established fact is the significant impact of the APOE gene on an individual’s risk for developing the condition. Depending on the variant inherited, one’s likelihood of suffering from this brain disorder can vary dramatically, ranging from half the average risk to more than twelve times it.
APOE gene variants are classified into three common types: 2, 3, and 4. Type 2 is linked to a reduced risk, type 3 is considered average, while type 4 is associated with a significantly heightened risk. The implications of these results are so profound that medical professionals often refrain from testing for APOE due to the distressing nature of potentially unfavorable results, especially given the absence of any cure or possibility to alter one’s genetic makeup.
However, a new development is on the horizon. Starting in May, a team of doctors in New York City plans to initiate a pioneering gene therapy trial. Participants with the highest-risk APOE variants will receive substantial doses of a safer gene variant directly into their brains. This innovative approach could not only slow the progression of Alzheimer's in diagnosed individuals but may also pave the way for preventative measures against the disease.
The first video outlines the complexities of Alzheimer's and dementia treatment, emphasizing the urgency for effective solutions.
Section 1.1: A New Approach to Gene Therapy
The clinical trial, spearheaded by Ronald Crystal at Weill Cornell Medicine in Manhattan, represents a novel strategy in the fight against dementia. Unlike traditional gene therapies that target rare diseases by correcting a single faulty gene, this trial seeks to mitigate the risk of Alzheimer’s through a different lens. The Alliance for Regenerative Medicine indicates that no gene therapies are currently being tested for Alzheimer’s, making this trial particularly groundbreaking.
“It may seem ambitious to transition this into human trials, but the need for any form of treatment is dire,” remarks Kiran Musunuru, a genetic researcher at the University of Pennsylvania. The New York experiment aims not to cure, but rather to reduce the likelihood of future disease among healthy individuals.
Subsection 1.1.1: Gene Therapy's Evolving Landscape
Crystal's approach circumvents the contentious discussions surrounding the root causes of Alzheimer’s, which has become a costly gamble for pharmaceutical companies and patients alike. Recent withdrawals of major studies, such as Roche's investigations into beta-amyloid-targeting antibodies, highlight the uncertainty in the field.
“There are strong advocates for the amyloid hypothesis,” Crystal states, “while others suggest that tau proteins play a crucial role.” He believes the truth is likely multifaceted and proposes a genetic perspective as a fresh avenue for exploration.
Chapter 2: Aiming for Prevention
The research team is building upon a discovery made 25 years ago when scientists at Duke University identified apolipoprotein E (the protein produced by the APOE gene) as a significant factor in Alzheimer’s. By analyzing genetic data from 121 patients, they found that the APOE4 variant was disproportionately present among those afflicted with the disease.
Despite the gene's unclear function—believed to assist in cholesterol and fat transport—its role as a risk factor remains alarming. The Alzheimer’s Association notes that approximately 65% of individuals with Alzheimer’s possess at least one copy of the high-risk gene. For those with two copies, the likelihood of developing dementia is nearly assured with age.
Yet, individuals carrying one copy of the high-risk variant along with one low-risk variant exhibit an average risk level, suggesting that the protective gene may counterbalance the harmful one. This is the effect that the Weill Cornell team aims to replicate. They are currently seeking participants who carry two copies of the high-risk gene and are experiencing memory issues or have already been diagnosed with Alzheimer’s.
In the upcoming trial, participants will receive spinal cord infusions of billions of viruses engineered to deliver the low-risk gene to their brains. Prior tests in monkeys indicated that the treatment could facilitate the spread of the beneficial gene throughout the brain. Additionally, mice subjected to similar treatments demonstrated reduced amyloid accumulation.
Crystal emphasizes that their strategy does not hinge on fully understanding the disease's mechanisms. “The genetic epidemiology surrounding Alzheimer’s is strikingly clear,” he asserts. “Our goal is to immerse the brain in E2, leveraging our existing infrastructure.”
The second video delves into the latest treatment options for Alzheimer’s disease, showcasing advancements and community discussions.
Section 2.1: The Future of Alzheimer's Treatment
This preliminary study by Crystal’s team seeks to ascertain whether the introduced gene is functioning effectively. They will analyze spinal fluid samples to check for the anticipated protein mix, specifically looking for a balance of type 4 with an equal or greater quantity of type 2.
It’s crucial to note that Alzheimer’s symptoms often appear after significant brain changes have occurred, typically a decade earlier. Thus, participants may not experience immediate benefits, given that they are already experiencing cognitive decline.
Nevertheless, the Alzheimer’s Drug Discovery Foundation has committed $3 million to support Crystal's research, marking its largest grant to date. “The outcome remains uncertain,” states Nick McKeehan, assistant director at the foundation. “Yet, this could be a pivotal step. It may prompt earlier interventions in treatment.”
Ultimately, the aspiration is that individuals with high-risk gene variants might receive a one-time genetic enhancement. Even a slight deceleration in the progression of brain degeneration could have substantial long-term benefits.
Susan Hahn, a genetic counselor, acknowledges the fear surrounding Alzheimer’s. “It’s often regarded as the most dreaded disease, as the thought of losing one’s mind is terrifying,” she notes. “Many would prefer a cancer diagnosis or heart disease. Genetic testing for APOE should be approached cautiously, as the results are permanent. However, this study might change that paradigm.”
Antonio Regalado serves as the senior editor for biomedicine at MIT Technology Review, focusing on how technology influences medicine and biomedical research. Prior to joining MIT Technology Review in July 2011, he reported on science, technology, and politics in Latin America from São Paulo, Brazil.